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The receptor tyrosine kinase RET is essential in a variety of cellular processes. RET gain-of-function is 3 
strongly associated with several cancers, notably multiple endocrine neoplasia type 2A (MEN 2A), while RET 4 
loss-of-function causes Hirschsprung’s disease and Parkinson’s disease. To investigate the activation 5 
mechanism of RET as well as to enable drug development, over-expressed recombinant protein is needed for 6 
in vitro functional and structural studies. By comparing insect and mammalian cells expression of the RET 7 
extracellular domain (RETECD), we showed that the expression yields of RETECD using both systems were 8 
comparable, but mammalian cells produced monomeric functional RETECD, whereas RETECD expressed in 9 
insect cells was non-functional and multimeric. This was most likely due to incorrect disulfide formation. By 10 
fusing an Fc tag to the C-terminus of RETECD, we were able to produce, in HEK293T cells, dimeric oncogenic 11 
RETECD (C634R) for the first time. The protein remained dimeric even after cleavage of the tag via the cysteine 12 
disulphide, as in full-length RET in the context of MEN 2A and related pathologies. Our work thus provides 13 
valuable tools for functional and structural studies of the RET signalling system and its oncogenic activation 14 
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 1 
1. Introduction  2 
Re-arranged during transfection (RET) receptor tyrosine kinase is a single-pass transmembrane protein that is 3 
important in multiple cellular processes including cell migration, proliferation, differentiation and maintenance 4 
[1–3]. RET is a versatile receptor tyrosine kinase that interacts through a co-receptor with four glial-cell-line-5 
derived neurotrophic factor (GDNF) ligands of the TGF-β superfamily (collectively, GFLs), GDNF, neurturin 6 
(NTRN), artemin (ARTN) and persephin (PSPN) as well as growth and differentiation factor 15 (GDF15), 7 
which is a distant relative of the GFLs [4–12]. RET has an extracellular domain (ECD) comprised of four 8 
cadherin-like domains (CLDs) and a cysteine-rich domain (CRD). Cryo-electron microscopy (cryo-EM) 9 
structures of RET in complex with its ligands show that the complex of dimeric GDNF ligands and co-10 
receptors recruits two molecules of RET to form a 2:2:2 C-clamp shaped complex. The RET ECD interacts 11 
with the co-receptors through its N-terminal domain and with the GDNF ligands through its C-terminal end; 12 
and correct folding and intermolecular interaction also requires the binding of calcium ions at CLD2-3 [13–13 
17] and possibly in the CRD as well [16]. RETCRD contains eight intramolecular disulfide bonds and exhibits 14 
a unique fold [16]. This is then followed by a transmembrane domain, an intracellular juxtamembrane region 15 
and a tyrosine kinase domain. RET signaling is mediated by binding of GFLs and GDF15 to their 16 
corresponding GDNF receptors (GFR1-4) or GDNF receptor-like (GFRAL), forming a complex that recruits 17 
RET to form an active heterohexameric complex that leads to the activation of RET at the tyrosine kinase 18 
domain for downstream cell signaling [15–17].  19 
 20 
Mutations in RET lead to a variety of human diseases. For example, gain-of-function mutations are strongly 21 
associated with cancers, including non-small-cell cancer (NSCC) and MEN 2A, while loss-of-function 22 
mutations contribute to Parkinson’s disease and Hirschsprung’s disease [1–3]. In the case of MEN 2A, point 23 
mutations of the cysteine residues in the CRD, most commonly C634R, lead to ligand-independent receptor 24 
activation [18,19]. In wild-type RET, C634 forms an intramolecular disulfide bond with C630 and, as a result, 25 
the oncogenic C634R mutation leaves C630 unpaired such that it can form intermolecular disulfide bonds 26 
[15,17]. The commonly accepted mechanism of activation is that C630 cross-links two RET molecules 27 
together via a C630-C630 disulfide bond, facilitating autophosphorylation and activation of the intracellular 28 
 4 
kinase domain (Fig. 1). However, previous reports suggested recombinantly expressed ECD of RETC634R 1 
mutant did not form a RET homodimer [15,20].  2 
 3 
Considering their clinical importance, RET and its complexes, as well as its oncogenic mutants, represent valid 4 
therapeutic targets. The FDA have approved a number of inhibitors targeting the intracellular domain of RET, 5 
such as cabozantinib, lenvatinib and selpercatinib for cancers associated with RET fusions or oncogenic 6 
mutations [21]. All of the approved inhibitors target multiple receptor tyrosine kinases (RTKs) due to the 7 
conservation of the intracellular kinase domain among different RTKs such as Trk and vascular endothelial 8 
growth factor (VEGF) receptors [22]. Therefore, drugs that specifically targeting RETECD or its complexes 9 
would have improved specificity and, presumably, fewer side-effects.  10 
 11 
To produce sufficient functional proteins for structural determination, eukaryotic proteins have been expressed 12 
recombinantly in a variety of expression hosts, including bacteria, yeast, insect cells and mammalian cells. The 13 
optimal host to use for protein over-expression is largely protein dependent. For the EGFR [23–26], Eph [27–14 
29] and Trk [30] RTKs, the extracellular domains or full-length receptors have been successfully expressed in 15 
both insect and mammalian expression systems. However, only mammalian cell expression, including CHO 16 
and HEK cells, has been reported to be successful for recombinant humanRET to generate protein for 17 
functional and structural studies [15–17,20,31]. On the other hand, baculovirus-infected insect cells have two 18 
advantages over mammalian cells: cost-efficiency and ease of large-scale expression. Moreover, insect cells 19 
are also capable of producing posttranslational modifications (PTMs), for instance, glycosylation, which is 20 
important for the folding and signaling of RTKs [32], making it a powerful system for recombinant eukaryotic 21 
protein expression.   22 
 23 
In the current study, we used both insect and mammalian cell expression systems to express the extracellular 24 
domain (ECD) of humanRET to investigate the impact of expression hosts on its function and describe the 25 
first overexpression and purification of the dimeric form of the extracellular domain of RET (C634R).  26 
 27 
  28 
 5 
 1 
2. Materials and methods 2 
2.1 Constructs  3 
All the constructs used in this study are summarized in Table 1. For RET expression in mammalian cells with 4 
its native signal peptide, wild-type humanRETECD (residues 1-635) and the mutants (C634R, C86R, C216S) 5 
were sub-cloned into pcDNA3.1 vector with a C-terminal Tobacco Etch Virus (TEV) protease cleavage site 6 
and His8-Flag (HF) tags. When Igκ and CD33 signal peptides were used, the mature wild-type humanRET
ECD 7 
(residues 28-635) was cloned into the vector with the same protease site followed by either a His8 (H) or HF 8 
tags. HumanRETECD-Fc harbouring the C634R (RETC634R-Fc) and C634R, C86R, C216S (RETC634R*-Fc) 9 
mutations were cloned into the same vector with C-terminal HF tags. Additionally, a G4S linker was cloned 10 
between the TEV protease cleavage site and the Fc tag in two of the RETC634R(*)-Fc contructs. 11 
 12 
Mature humanGDF15 (residues 195-308) preceded by an N-terminal modified Fc tag with a thrombin cleavage 13 
site was cloned into the pcDNA3.1 vector, and a modified Fc protein [33,34] was cloned into the pIRES-eGFP 14 
vector. Both the Fc and Fc-GDF15 expression constructs use the Igκ signal peptide for protein secretion and 15 
were used for co-expression. For RET expression in insect cells, wild-type humanRETECD (28-635) was sub-16 
cloned into a pK503.9 vector (modified from pFastBac vector) [35] with N-terminal Flag-His8 (FH) tags and 17 
a thrombin cleavage site. HumanGFRALECD (residues 19-351) with a C-terminal TEV cleavage site and His8-18 
twin Strep (HS) tags was cloned into pK503.9 vector and is referred to as GFRAL in this study.  19 
 20 
2.2 Cell culture and protein expression  21 
An adherent culture of HEK293T cells (American Type Culture Collection, CRL-3216) was maintained in 22 
Dulbecco's Modified Eagle Medium (DMEM) (Sigma-Aldrich, D6429) supplemented with 10% heat-23 
inactivated fetal bovine serum (FBS) (Gibco) at 37 ˚C, 5% CO2. CHO-K1 and CHO cells (kind gifts from Dr. 24 
Helena Vihinen and Prof. Mart Saarma, respectively, University of Helsinki) were maintained in the same 25 
medium supplemented with 1x non-essential amino acids (NEAA) solution (Lonza). On the day of transfection, 26 
conditioned medium was replaced with fresh DMEM medium with 4% FBS and antibiotic-antimycotic 27 
mixture (Gibco). NEAA solution was added to the medium when CHO-K1 and CHO cells were used. 28 
 6 
HumanRET plasimds were mixed with polyethylenimine (PEI) (Polysciences Europe GmbH) [36] in a 1:3 1 
molar ratio at room temperature (RT) in DMEM medium, the ratio of which was optimized for RET expression 2 
(Supplementary Fig. 1A), without FBS or antibiotics for 8 min prior to transfection. For the expression of 3 
Fc-GDF15, conditioned medium was replaced with DMEM medium containing 1x lipid mixture solution 4 
(PeproTech) and 1x serum replacement solution (PeproTech) with antibiotic-antimycotic mixture. Fc-GDF15 5 
and Fc plasmids were mixed at a 2:1 ratio for co-expression and the mixed plasmids were then incubated with 6 
PEI in a 1:2.5 molar ratio at RT for 8 min before transfection.  7 
Spodoptera frugiperda (Sf 9) and Trichoplusia ni High Five (Hi5) cells (Thermo Fisher Scientific) were 8 
cultured in suspension at 27 ˚C in Xpress medium (Lonza). Bacmid DNAs containing RETECD and GFRAL 9 
genes were generated and transfection and baculovirus generation was performed as previously described [37]. 10 
Baculovirus-infected insect cells (BIIC) were prepared and used for large-scale expression [37].  11 
 12 
2.2.1 Expression optimization 13 
After the addition of PEI/DNA mixture, cells were incubated at 37 ˚C for 24 h and expression tests were run 14 
at either that temperature or at 33 ˚C after the initial incubation at 37 ˚C. Supernatant (SN) samples were taken 15 
daily from 4 to 7 days after transfection for HEK293T cells and from 4 to 11 days after transfection for CHO-16 
K1 cells. On Day 7 post-transfection HEK293T cells started to look unhealthy; therefore, we stopped collecting 17 
samples for assessing expression.  18 
 19 
2.2.2 Large-scale expression 20 
For large-scale expression of RETECD and Fc-GDF15, adherent HEK293T cells were cultured in either roller 21 
bottles (Greiner Bio-One GmbH) at 2 rpm, or 5-layerred flasks (Falcon™, Fisher Scientific) at 37 ˚C, 5% CO2. 22 
After transfection, the expression of RETECD and Fc-GDF15 continued for 7 and 5 days, respectively. For 23 
expressing RETECD in insect cells, Sf 9 cells were infected at a cell density of 1 million cells/ml with one vial 24 
of BIIC (1x107 infected cells) per liter culture. GFRAL was expressed using Hi5 cells at the same density with 25 
two vials of BIIC (2x107 infected cells) per liter culture. The amount of BIIC to use for large-scale expression 26 
was optimized for each construct so that proliferation arrest was achieved 24-h post-transfection. The 27 
expression of RETECD and GFRAL was then carried out for 72 h and 68 h, respectively.    28 
 7 
 1 
2.3 Protein purification 2 
Cell culture medium containing the secreted proteins was harvested after the indicated expression time by 3 
centrifuging at 4000 rpm for 15 min at 4 ˚C to pellet the cells. For volumes larger than 1 litre, the cleared 4 
supernatant was concentrated and buffer-exchanged using a Pellicon concentrator (Millipore EMD). 5 
Membranes with a molecular weight (MW) cut off of 10 kDa were used for Fc-GDF15 and GFRAL and with 6 
a cut off of 30 kDa for RETECD. RETECD expressed using insect and mammalian cells was first immobilized 7 
on Ni-NTA resin (Qiagen) and the bound protein was eluted with buffer containing 125 mM imidazole. The 8 
elutae was further purified using anti-Flag (GenScript) affinity chromatography and 300 g/ml poly-Flag 9 
peptide (Bimake) was used for protein elution from anti-Flag resin. Purified RETECD was concentrated with 10 
Amicon centrifuge concentrators (30 kDa) and buffer-exchanged into 20 mM HEPES pH 7.5, 150 mM NaCl, 11 
1 mM CaCl2 with 10% glycerol. RET
C634R*-Fc was purified as for RETECD if the Fc tag was not to be cleaved. 12 
After peptide elution, RETC634R*-Fc was buffer exchanged and concentrated with Amicon centrifuge 13 
concentrators (50 kDa).  14 
 15 
To purify the extracellular domain of RETC634R* dimer, medium containing RETECD-Fc was incubated with 16 
pre-equilibrated Protein A resin (GenScript) in binding buffer containing 20 mM HEPES pH 7.5, 150 mM 17 
NaCl, 1 mM CaCl2. After washing, His-tagged TEV protease was added to the resin at a molar ratio of 1:10 18 
and the mixture was incubated overnight at 4 ˚C. The cleaved product was loaded onto a HisTrap column (GE 19 
Healthcare) to remove impurities, including HIS tags, un-cleaved products and TEV protease and cleaved 20 
RETC634R* was eluted at a low imidazole concentration by gradient elution. The fractions containing RETC634R* 21 
were concentrated with Amicon centrifuge concentrators (50 kDa) and then purified using size exclusion 22 
chromatography (SEC) on a Superdex 200 increase 5/150 GL column (GE Healthcare) in 20 mM HEPES pH 23 
7.5, 100 mM NaCl, 1 mM CaCl2.  24 
 25 
Fc-GDF15 was purified using Protein A resin and eluted using 100 mM sodium citrate, 100mM NaCl, pH 3.1. 26 
The eluate was collected drop by drop into 100 l of neutralization buffer containing 1 M Tris pH 8.8 per ml 27 
of eluate and the fractions containing Fc-GDF15 were concentrated and buffer exchanged into Tris-buffered 28 
 8 
saline (TBS) pH 7.5. GFRAL was purified using Strep-Tactin resin (IBA Lifesciences) and eluted with elution 1 
buffer containing 20 mM HEPES pH 7.2, 150 mM NaCl, 5 mM d-Desthiobiotin (IBA Lifesciences). Elution 2 
fractions were collected, concentrated and further purified either using SEC on a Hiload Superdex 200 pg 3 
16/600 (GE Healthcare) or a Superdex 200 increase 10/300 column (GE Healthcare) in 20 mM HEPES pH 4 
7.2, 150 mM NaCl.  5 
 6 
2.4 Pull-down assays  7 
2.4.1 Activity assessment of insect cell- and mammalian cell-expressed RETECD 8 
Fc-GDF15 dimer and GFRAL were first incubated together on ice for 15 min. RETECD expressed using either 9 
Sf 9 or HEK293T cells was then added to the mixture. The final molar ratio of Fc-GDF15 dimer:GFRAL:RET 10 
in the mixture was 1:2:2 (1.25:2.5:2.5 M). After incubating the samples on ice for 1 h, 5 l of pre-equilibrated 11 
protein A resin in binding buffer containing 20 mM HEPES pH 7.5, 150 mM NaCl, 2 mM CaCl2, 5% glycerol 12 
and 0.05% Tween-20 was added to each sample to immobilize Fc-GDF15 via the Fc to pull down either 13 
GFRAL or GFRAL and RETECD. To assess the level of non-specific binding, the same amount of resin was 14 
added to samples that only contained RETECD. Binding buffer was added to each sample to make a final volume 15 
of 400 l and the samples were incubated at 4 ˚C for 1 h with end-to-end rotation. After incubation, the resin 16 
was pelleted by centrifuging at 700 x g for 2 min at 4 ˚C and washed three times with 500 l binding buffer. 17 
Finally, 15 l of binding buffer was added to each sample with SDS polyacrylamide gel electrophoresis (SDS-18 
PAGE) sample loading buffer without Dithiothreitol (DTT) to release any bound proteins on the resin for SDS-19 
PAGE and western blotting (WB) analysis with anti-HIS antibody (Qiagen) and anti-mouse-horseradish 20 
peroxidase (HRP) secondary antibody (m-IgGκ BP-HRP, Santa Cruz Biotechnology).  21 
 22 
2.4.2 Analysis of the expression of RETC634R(*) dimer 23 
HEK293T cells were plated in 12-well tissue culture plates one day before transfection and PEI transfection 24 
was carried out as described above at 70% cell confluency. As a negative control, PEI without any plasmid 25 
was added to the cells. Supernatant containing the expressed proteins (RETC634R(*)-(G4S)-Fc and 26 
RETC630A,C634R-Fc) as well as the control sample was collected 7 days post transfection and centrifuged at high 27 
 9 
speed to remove cell debris. Pre-washed protein A resin (10 l) was directly added to the clarified media. 1 
Incubation and washes were performed as described above. After the washing step, 250 l binding buffer was 2 
added to each sample and 60 l of the resuspended mixture with beads was collected for SDS-PAGE to analyse 3 
the expression of the Fc-tagged proteins. His-tagged TEV protease (20 g) was added to each sample and 4 
incubated at 4 ˚C overnight without agitation. The next day, another 60 l of the resuspended sample was 5 
collected to examine total proteins in each sample as well as the cleavage efficiency of TEV protease. The rest 6 
of the sample was centrifuged to remove the remaining resin and the supernatant was taken for further analysis.  7 
Samples collected before and after the addition of the protease were mixed with SDS-PAGE loading buffer 8 
with or without DTT to evaluate the disulfide-bonded RETC634R(*)-(GS)-Fc and RET C634R(*) homodimers. The 9 
proteins were resolved on 4–20% gradient gels (Bio-Rad), which were subsequently analysed by western blot 10 
with anti-RET(C3)-HRP antibody (Santa Cruz Biotechnology). 11 
 12 
2.5 Blue native PAGE to visualize complex formation  13 
For the formation of the RETECD/Fc-GDF15/GFRAL complex, Fc-GDF15 dimer was incubated with GFRAL 14 
for 15 min prior to the addition of RETECD. The final volume was 10 l, and the final concentrations of Fc-15 
GDF15 dimer, GFRAL and RETECD are 1.75 M, 3.5 M and 3.5 M, respectively. Fc-GDF15/GFRAL was 16 
prepared in the same way without the addition of RETECD. The protein mixtures were incubated at 4 ˚C for 1 17 
h before the addition of the blue native (BN) PAGE sample buffer. Electrophoresis was carried out using 4–18 
20% gradient gels and run at 100 V for 3.5 h at 4 ˚C as previously described [37,38]. Gels were destained using 19 
destaining solution containing 20% methanol and 10% acetic acid and the solution was changed every 20 min 20 
until the protein bands were clear against the background.  21 
 22 
2.6 Bio-layer interferometry technology system (BLItz)  23 
Anti-hIgG Fc capture (AHC) biosensors (FortéBio) were pre-hydrated in buffer containing 20 mM HEPES pH 24 
7.5, 150 mM NaCl, 1 mM CaCl2 with 0.05% Tween-20 for at least 10 min. Measurements were taken using a 25 
BLItz instrument (FortéBio) in 7 steps: initial baseline (30 s), loading (120 s), baseline (60 s), association 1 26 
(180 s), baseline (60 s), association 2 (180 s) and dissociation (180 s). Fc-GDF15 was immobilized to AHC 27 
 10 
sensor tips at a concentration of 15 M in the loading step and GFRAL at a concentration of 3 M was used 1 
to saturate the immobilized Fc-GDF15 in the first association step. A concentration series of 0.11, 0.56, 1.2, 2 
2.8, 7, 14 and 28 M of RETECD (mammalian) and a concentration series of 1.2, 2.8, 7, 14 and 28 M of 3 
RETECD (insect) were used in the second association step to bind to the pre-formed Fc-GDF15/GFRAL 4 
complexes. Experiments were performed in triplicate for RETECD (mammalian) and in duplicate for RETECD 5 
(insect) independently. The sensorgrams of the association of RETECD as well as the saturation binding curves 6 
were plotted with GraphPad Prism 8. The concentration of RETECD was transformed to logarithmic scale and 7 
fitted using a nonlinear regression sigmoidal model to calculate the dissociation constant (Kd).   8 
 11 
 1 
3. Results  2 
3.1 The impact of expression host on the activity of the extracellular domain of RET receptor 3 
tyrosine kinase 4 
To establish the optimum expression system for RETECD, we evaluated three mammalian (HEK293T, CHO-5 
K1 and CHO) and two insect (Sf 9 and Hi5) cell expression systems. 6 
3.1.1 RETECD expression using mammalian cells 7 
We evaluated a range of purification tags (His8 (H) and His8-Flag (HF)) tags and secretion signal peptides for 8 
RETECD expression in HEK293T cells using transient expression. The expression yield proved to be critically 9 
dependent on the signal peptide, with the native signaling peptide giving the highest expression yield (Table 10 
2). The construct RETECD-HF with the native peptide was thus chosen for expression optimization and the 11 
expression product using this construct is referred to as RETECD (mammalian) from here onwards. 12 
 13 
Expression tests of RETECD in CHO-K1 and CHO cells showed that CHO cells expressed less RETECD than 14 
CHO-K1 cells under same expression conditions (Supplementary Fig. 1B); thus, the expression optimization 15 
of RETECD was carried out using HEK293T and CHO-K1 cell lines (Fig. 2). CHO-K1 cells expressed more 16 
RETECD when incubated at 33 ˚C rather than 37 ˚C, while HEK293T cells showed the opposite temperature 17 
dependency for RETECD expression. The highest expression level was achieved 7 days after transfection at 37 18 
˚C using HEK293T cells and there is no apparent difference in the ligand-binding capacity of RETECD 19 
expressed using HEK393T and CHO-K1 cells (Supplementary Fig. 2). In our laboratory, the yield of purified 20 
RETECD is 0.8 – 1 mg per liter of HEK293T culture.  21 
 22 
 23 
3.1.2 RETECD expression using insect cells 24 
To express RETECD using insect cells, we used the baculovirus expression vector system (BEVS). Because 25 
insect cells use different secretion signal peptides than mammalian cells, we did not use the native peptide of 26 
RET but the signal peptide from ecdysteroid UDP-glucosyltransferase [35]. Maximum expression of RETECD 27 
was observed 72 hours post infection. The yield of purified RETECD is around 1 mg per liter of Sf 9 cell culture. 28 
 12 
When expressed using Hi5 cells, almost all RETECD was seen in the cells instead of being secreted into the 1 
medium (data not shown), and so these cells were not used for further studies. RETECD expressed using Sf 9 2 
cells is referred to as RETECD (insect). 3 
 4 
 5 
3.1.3 Comparison of purified RETECD expressed using insect and mammalian cells 6 
RETECD undergoes extensive post-translation glycosylation and has 12 predicted glycosylation sites, although 7 
the functional significance of these is not well understood. Based on their electrophoretic migration on SDS-8 
PAGE under reducing conditions, we observed RETECD (mammalian) and RETECD (insect) to have molecular 9 
weights of 120 kDa and 95 kDa respectively (Fig. 3A) versus a calculated peptide mass for this construct of 10 
71 kDa. These differences in apparent MW are due to varying degrees of post-translational glycosylation, 11 
presumably as a result of the different glycosylation machinery in mammalian and insect cell systems [39,40]. 12 
As shown in Fig. 3, RETECD (insect) showed a higher level of heterogeneity under non-reducing conditions, 13 
consisting of monomer, dimer and larger oligomers and the oligomers are presumably linked by disulfide 14 
bonds as they were reduced to monomer after the addition of DTT (Fig. 3A). Two extra bands below the full-15 
length RETECD (insect) were observed, which is possibly due to degradation at the C-terminus of RETECD 16 
(insect) because the proteins were reactive towards anti-RET (C-3) antibody (right panel, Fig. 3A) and were 17 
sensitive to PNGase treatment similarly to full-length RETECD (insect) (Supplementary Fig. 3). In comparison, 18 
RETECD (mammalian) mainly existed as monomer under both reducing and non-reducing conditions in SDS-19 
PAGE. Separated under their native conditions in BN PAGE, higher order oligomeric RETECD (insect) bands 20 
were observed, while RETECD (mammalian) exits mainly as monomers, consistent with the results of SDS-21 
PAGE (Fig. 3B). In addition, further characterization by SEC showed a single peak for RETECD (mammalian), 22 
suggesting a homogenous protein sample, while a large proportion of RETECD (insect) eluted earlier than 23 
RETECD (mammalian). The results further confirmed the differences in the oligomeric states between RETECD 24 
(mammalian) and RETECD (insect). 25 
 26 
 27 
3.1.4 Difference in activity of RET ECD expressed using insect and mammalian cells  28 
 13 
To assess the activity of RETECD (mammalian) and RETECD (insect), we first used pull-down assays to see 1 
whether they could form a complex with GDF15/GFRAL. RETECD (mammalian) was clearly pulled down by 2 
GDF15/GFRAL (Fig. 4A). The signal strength for pull down of RETECD (insect) was only slightly stronger 3 
than that of the bead control, indicating that only a low percentage (2%) of RETECD (insect) is active. To 4 
calculate the relative activity of RETECD (mammalian) and RETECD (insect) in binding to GDF15/GFRAL, we 5 
compared the intensity of the RETECD bands for both input and pull-down samples. RETECD (mammalian) is 6 
over 25 times more active than RETECD (insect) (Fig. 4B).  7 
 8 
Additionally, BN PAGE was used to detect RET/GDF15/GFRAL complex formation. As expected, 9 
GDF15/GFRAL complex formation as well as its complex with RETECD (mammalian) (marked by the red star, 10 
Fig. 5) were observed, confirming their binding capacity. However, no complex formation was seen when 11 
RETECD (insect) was together with GDF15/GFRAL, and the band intensity of monomer and dimer RETECD 12 
(insect) did not change upon the addition of the ligands.  13 
 14 
To orthogonally and quantitatively validate these results, we used BLItz to measure the binding affinity 15 
between RETECD and GDF15/GFRAL. Accordingly, Fc-GDF15/GFRAL was immobilized on anti-hIgG Fc 16 
biosensors and the concentration dependent binding of both RETECD (mammalian) and RETECD (insect) was 17 
measured (Fig. 6A). In accordance with our previous results, no binding was observed for RETECD (insect) 18 
even at the highest concentration (28 µM) (Fig. 6B). Conversely, we observed a concentration dependent 19 
association signal for RETECD (mammalian), giving a calculated Kd of 3.2 M (2.0 – 5.2 M, 95% confidence 20 
interval) for binding to Fc-GDF15/GFRAL (Fig. 6C and 6D).  21 
 22 
3.2 Recombinant expression of oncogenic mutant RETC634R 23 
The oncogenic C634R mutation of RET is one of the most common driver mutations associated with MEN 24 
2A and, in the context of full-length RET, is known to drive ligand-independent dimerization of RET. However, 25 
previous studies have found that the extracellular domain carrying the C634R mutation does not dimerize 26 
when recombinantly expressed, bringing the mechanism of action into question. We sought to use our 27 
optimized expression system to interrogate the questions posed by these findings. Therefore, we introduced 28 
 14 
the C634R mutation into our optimized expression construct for the ECD of RET and tested the expression in 1 
HEK293T cells. Consistent with the previous reports [15,20], we found that the ECD of RETC634R expressed 2 
well but existed solely as a monomer, demonstrating that C630 had not formed an intermolecular disulfide 3 
bond. We hypothesized that alternative C630 oxidation processes (eg to sulfinic acid or sulfonate [41]) might 4 
be occurring faster than disulfide-induced dimerization of RETC634R because of the low RET concentration 5 
when recombinantly expressed into the oxidizing extracellular medium (Fig. 7, upper panel). Therefore, we 6 
incorporated a C-terminal Fc tag into the construct to mimic the higher local RET concentrations found in the 7 
membrane for full-length oncogenic RET as we expected that intermolecular C630-C630 disulfide formation 8 
would then occur (Fig. 7, lower panel). Following expression and purification of RETC634R-Fc, SDS-PAGE 9 
analysis revealed that RETC634R-Fc exists in dimeric form (MW ~ 300 kDa under non-reducing conditions) and 10 
becomes monomeric under reducing conditions (MW ~ 150 kDa) (Fig. 8). Following cleavage of the Fc tag 11 
by TEV protease, RETC634R remained mainly dimeric (MW ~ 240 kDa under non-reducing conditions) 12 
indicating that the Fc tag had induced the expected RET homodimerization and the dimer was not held together 13 
only by the Fc. Upon treatment with reducing agent, RETC634R was resolved entirely as a monomer (MW ~ 14 
120 kDa) (Fig. 8), demonstrating that the mechanism of homodimerization is via disulfide bond formation, 15 
supporting our hypothesis. To verify that the disulfide bond formation is through C630, we expressed and 16 
purified RETC630A,C634R-Fc. This construct expressed well but, after cleavage of Fc tag, was entirely monomeric 17 
(Supplementary Fig. 4). That the additional C630A mutation abolishes the propensity for RET to dimerize 18 
provides further support that the mechanism of C634R dimerization is through intermolecular C630-C630 19 
disulfide bond formation. 20 
 21 
Apart from C630, RETC634R contains two additional cysteine residues, C87 and C216, which are known to be 22 
unpaired and surface exposed in wild type RET. To eliminate the possibility that C87 or C216 might be the 23 
source of intermolecular disulfide induced RET dimerization, we generated a mutant construct, RETC87R, C216S, 24 
C634R (RETC634R*-Fc), for which C630 is the only unpaired cysteine (Table 1). Similar to RETC634R, the 25 
RETC634R* mutant remained dimeric after the Fc tag removal, confirming the hypothesis that it is only the 26 
C630-C630 disulfide bond that causes dimerization (Fig. 8). Moreover, RETC634R*-Fc showed improved 27 
 15 
expression compared to RETC634R-Fc, which is consistent with previous reports where the C87R and C216S 1 
mutations have been introduced to wild-type RETECD [31].  2 
 3 
To improve the protein yield further, we generated two additional constructs containing a G4S linker between 4 
the cleavage site and the Fc tag but found that this had no significant impact on either expression level or the 5 
efficiency of TEV protease cleavage (Fig. 8). Because the RETC634R*-Fc gave higher expression than RETC634R-6 
Fc, we scaled up expression of RETC634R*-Fc in HEK293T cells without the G4S linker for further 7 
characterization. Following our expression and two-step purification protocol, we obtained RETC634R*-Fc 8 
dimer with a yield of 2.9 mg per liter of culture and a purity higher than 90%, calculated based on the band 9 
intensity of the Coomassie-stained SDS-PAGE (Fig. 9A). For the purification of RETC634R*, following TEV 10 
protease cleavage, the dimer was co-purified with a 25% contamination of RETC634R* monomer. These could 11 
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 16 
 1 
4. Discussion  2 
Both insect and mammalian cell expression systems have been used for recombinant protein expression of 3 
either the extracellular domains or full-length RTKs. So far, only mammalian cells have been reported to 4 
express RETECD; we therefore compared the expression of RETECD in insect cells to its expression in 5 
mammalian cells. The expression levels of RETECD in both systems were comparable, yielding 0.8-1 mg per 6 
liter culture. However, only RETECD (mammalian), not RETECD (insect), can bind to its ligands (Fig. 3 and Fig. 7 
4). Glycosylation is known to be important for the proper folding of RET and other RTKs [20,32,42,43]. We 8 
observed that both RETECD (mammalian) and RETECD (insect) were heavily glycosylated, with RETECD 9 
(mammalian) carrying approximately 51 kDa of glycosylation and RETECD (insect) approximately 24 kDa (Fig. 10 
3A). The difference in the glycosylation level was expected as mammalian cells produce more complex glycan 11 
chains in their N-glycan processing pathway than insect cells [44]. One way to assess whether glycoproteins 12 
have been properly post-translationally processed is to measure their sensitivity to PNGase and Endo H [45,46]: 13 
In the Golgi, complex N-glycans are added to the glycoproteins, rendering them Endo H-resistant [47]. In our 14 
study, RETECD (insect) was secreted by Sf 9 insect cells and the purified protein was sensitive to PNGase but 15 
not Endo Hf (Supplementary Fig. 3), indicating that the protein was processed through the ER and Golgi. 16 
However, RETECD expressed in Hi5 cells could not be secreted, suggesting substantial misfolding of RETECD 17 
in Hi5 cells and indicating that different insect cell lines express complex mammalian proteins differently.   18 
 19 
HumanRETECD contains 28 cysteine residues. Apart from two unpaired cysteines, C87 and C216, the others 20 
form 13 intramolecular disulfide bonds, which gives rise to the risk of disulfide mismatching during post-21 
translation processing. The CLDs 1-3 of humanRET have also been reported to be more prone to misfold when 22 
compared to the non-mammal species [20]. In our study, RETECD expressed using Sf 9 cells exhibited various 23 
higher order oligomeric states cross-linked by disulfide bonds (Fig. 3). While RETECD (mammalian) could 24 
form a complex with GDF15/GFRAL with a Kd of 3.2 M, little or no apparent complex formation was seen 25 
between RETECD (insect) and GDF15/GFRAL (Figs. 4-6). To our knowledge, this is the first time the affinity 26 
between humanRETECD and GDF15/GFRAL has been quantitatively reported. Although different to that 27 
reported for humanRETECD binding to GDNF/GFR1-Fc (15 nM) measured by enzyme-linked 28 
 17 
immunosorbent assay (ELISA) [31], the measured affinity is similar to that reported for zebrafishRETECD 1 
binding to GDNF/GFR1 (5.9 M) measured, as we did, by BLItz [48]. Such conservation of affinity is 2 
expected as a result of the conserved activation mechanism among GFLs and GDF15 signalling through RET 3 
[9,16] and is further demonstration that our proteins are fully active. Overall, the results suggest that insect 4 
cells do not express functional humanRETECD, likely due to disulfide-mismatch-induced misfolding. This may 5 
explain why, when expressed in Hi5 cells, humanRETECD could not be secreted [49], even though we 6 
previously showed that Hi5 cells could express functional, monomeric zebrafishRETECD, which contains fewer 7 
cysteine residues compared to humanRETECD [37]. 8 
 9 
Different approaches have been reported for the expression of recombinant humanRETECD using mammalian 10 
cells (Supplementary Table 1). In our study, we compared transient expression of RETECD in HEK293T, 11 
CHO-K1 and CHO cells. We found that HEK293T cells showed highest expression, CHO-K1 cells second, 12 
and CHO cells expressed most poorly (Fig. 2 and Supplementary Fig. 1). In accordance with previous results 13 
[20], the expression of RETECD is better at lower temperature using CHO-K1 cells, but we observed high 14 
expression of RETECD using HEK293T cells only at 37 °C (Fig. 2). It is likely that the higher expression level 15 
results from a balance between the high cellular activity of HEK cells at 37 ˚C and rate-limiting misfolding 16 
potential. Furthermore, we used HEK293T cells to express some of the RETECD glycosylation mutants (N336Q, 17 
N343Q and N468Q) (Table 1). We found that the expression level of RETN336Q was similar to that of wild-18 
type RETECD (0.8-1 mg per liter culture) while that of two other mutants, N343Q and N468Q, was three times 19 
lower (0.3 mg per liter culture) (Supplementary Fig. 5A). Based on the result from pull-down assays, the 20 
binding capacity of the purified mutants (N336Q and N343Q) to GDF15/GFRAL is comparable to that of the 21 
wild-type RETECD (Supplementary Fig. 5B and 5C). It would be interesting to further investigate whether 22 
these or other glycosylation mutants significantly impact RET stability and function.   23 
 24 
RET dimerization of the oncogenic C634R mutant is one of the most common mechanisms causing MEN 2A. 25 
Here we demonstrated that, by attaching a C-terminal Fc tag to RETC634R, the extracellular domain of the 26 
oncogenic mutant could be expressed and purified in its dimeric form. Previous attempts showed that the 27 
recombinantly expressed ECD of soluble RET C634R showed no apparent difference to that of wild type RET 28 
 18 
[15,20], but dimerization of full-length RETC634R has been reported to occur readily [50–53]. We hypothesized 1 
that the dimerization of full-length mutant RET via cysteine residue C630 occurs due to the high effective 2 
concentration of RET in the membrane and the fact that all of the protein is correctly oriented to place the two 3 
C630s near each other. Conversely, in soluble RETECD expressed recombinantly, C630 will be oxidized eg to 4 
sulfinic acid and sulfonates [41] at the low protein concentrations present in the extracellular medium, thus 5 
disfavoring RET-RET dimerization (Fig. 7). Therefore, the addition of the Fc tag to the C-terminus of RET, 6 
bringing the C-terminus of two RETECDs close to each other, would enable the dimer formation of soluble 7 
RETC634R. Our results were consistent with this: we obtained 75% of dimeric RETC634R* after tag removal (Fig. 8 
9). There are two explanations for why 25% remained monomeric. One possibility is that this is an artefact 9 
introduced by the reducing reagent (50 M TCEP) that is necessary for efficient proteolytic tag removal by 10 
TEV protease; the other is that there is only 75% formation of the C630 crosslink. This could be tested by 11 
using cysteine-independent proteases for tag removal, such as Thrombin, to enable cleavage of the Fc tag under 12 
non-reducing conditions.  13 
 14 
Our studies of RETECD expressed using insect and mammalian cells showed the impact of the eukaryotic 15 
expression hosts on protein function and emphasize that caution should be taken when using insect cell 16 
expression systems especially for cysteine-rich and highly glycosylated proteins that are prone to misfold. 17 
Successful purification of soluble dimeric RETC634R provides a route for further functional and structural 18 
studies to understand oncogenic activation of RET and its role in driving cancers such as MEN 2A.  19 
  20 
 19 
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 Table 1. A summary of transfection constructs used in this study. 2 
 3 
 4 
  5 
Construct  Cloned 
residues 
Signal peptide Vector Referred in 
this paper  
RETECD-TEV-H 28-635 Igκ pcDNA3.1  
RETECD-TEV-HF 28-635 Igκ pcDNA3.1  
RETECD-TEV-HF 28-635 CD33 pcDNA3.1  
RETECD-TEV-HF 1-635 Native pcDNA3.1 RETECD 
(mammalian) 
RETECD(C634R)-TEV-Fc-HF 1-635 Native pcDNA3.1 RET
C634R-Fc 
RETECD(C634R)-TEV-G4S-Fc-HF 1-635 Native pcDNA3.1  
RETECD(C634R, C87R, C216S)-
TEV-Fc-HF 
1-635 Native pcDNA3.1 RETC634R*-Fc 
RETECD(C634R, C87R, C216S)-
TEV-G4S-Fc-HF 
1-635 Native pcDNA3.1  
RETECD(C630A, C634R)-TEV-Fc-
HF 
1-635 Native pcDNA3.1 RETC630A,C634R-
Fc 
RETECD(N336Q)-TEV-HF 1-635 Native pcDNA3.1 RETN336Q 
RETECD(N343Q)-TEV-HF 1-635 Native pcDNA3.1 RETN343Q 
RETECD(N468Q)-TEV-HF 1-635 Native pcDNA3.1 RETN468Q 
Fc-Thrombin-GDF15 195-308 Igκ pcDNA3.1 Fc-GDF15 
Fc / Igκ pIRES-eGFP  








Table 2. Expression test of RETECD with different secretion peptides and tags using HEK293T cells. H: His8 1 
tag; HF: His8-Flag tag.  2 
Signal 
peptide 
Signal peptide sequence Protein of 
interest 
Estimated yield 
(mg) per liter 
Igκ METDTLLLWVLLLWVPGSTGD RETECD-H 0.02 
RETECD-HF 0.10 
CD33 MPLLLLLPLLWAGALAM RETECD-HF 0.45 
Native  MAKATSGAAGLRLLLLLLLPLLGKVALG RETECD-HF 3.00 
 3 
  4 
 26 
Figure legends 1 
Figure 1. Schematic representation of RET activation mechanisms. RET is colored blue, GFRAL red and 2 
GDF15 yellow. The coils represent transmembrane helices; GFRAL, as RET, has a single transmembrane 3 
helix. P represents phosphorylated tyrosine residues after receptor activation. 4 
 5 
Figure 2. Time and temperature dependent comparison of the expression level of RETECD using HEK293T 6 
and CHO-K1 cell lines. Protein expression level of RETECD was calculated based on band intensity reading 7 
from ImageJ [54] (Supplementary Fig. 1C). Expression level under each condition is normalized against the 8 
highest expression value (Day 7, HEK293T 37 ˚C). Because the majority of HEK293T cells were dying 7 days 9 
post transfection, samples were not taken afterwards. 10 
 11 
 12 
Figure 3. Purified RETECD expressed using insect and mammalian cells. A) Coomassie-stained SDS-PAGE 13 
image and anti-RET WB showing purified RETECD (2 g) under reducing and non-reducing conditions; B) BN 14 
PAGE using 1 g and 2 g of RETECD showing the oligomeric state of purified RETECD; C) SEC profile 15 
showing different RETECD expressed using insect (blue) and mammalian cells (beige). M(i): monomeric 16 
RETECD (insect); D(i): dimeric RETECD (insect); O(i): oligomeric RETECD (insect); M(m): monomeric RETECD 17 
(mammalian); D(m): dimeric RETECD (mammalian). 18 
 19 
Figure 4. Pull-down of RET expressed using insect and mammalian cells by Fc-GDF15/GFRAL using protein 20 
A resin showing that both Fc-GDF15 and GFRAL are required to pull down RET, and that they pull down 21 
mammalian-expressed RET. A) Left panel shows Coomassie-stained SDS-PAGE image. The area shown in 22 
dotted lines was subject to anti-HIS WB (right panel). All samples were treated with SDS loading dye without 23 
DTT. Under the denaturing conditions, Fc-GDF15 appears as two major bands with the high MW band being 24 
dimeric Fc-GDF15 and the low MW band being Fc. M(i): monomeric RETECD (insect); D(i): dimeric RETECD 25 
(insect); M(m): monomeric RETECD (mammalian). B) The table shows the band intensity measured by ImageJ 26 
 27 
(Area (U)). Bands correspond to RETECD monomers are labelled (1 for RETECD (insect) and 2 for RETECD 1 
(mammalian)). U: units. 2 
Figure 5. BN PAGE image showing complex formation of RET/GDF15/GFRAL complex with RETECD 3 
(mammalian) but not with RETECD (insect). The red star marks the band corresponding to the 4 
RET/GDF15/GFRAL complex and the black stars mark the bands corresponding to the GDF15/GFRAL 5 
complex. The band observed above the complex band may be attributed to a higher order complex. Fc-GDF15 6 
appears as three bands with the major band corresponding to the desired dimeric Fc2-GDF15 while the minor 7 
bands likely arise from partial Fc dissociation during PAGE. 8 
 9 
Figure 6.  Measurement of the binding of RETECD for Fc-GDF15/GFRAL using BLItz. A) Schematic 10 
diagram of the experimental setup using BLItz; B,C) Sensorgrams of RETECD (insect) (B) and RETECD 11 
(mammalian) (C) binding to Fc-GDF15/GFRAL immobilized on anti-hIgG Fc (AHC) biosensors at the 12 
indicated concentrations; D) Saturation binding curves fitted with nonlinear regression sigmoidal model after 13 
transforming the concentration to logarithmic scale. CI: Confidence interval.          14 
 15 
 16 
Figure 7. Schematic representation of different approaches to produce the extracellular domain of RETC634R. 17 
Upper panel showing the expression of soluble RETC634R with a possibly oxidized [O] C630 residue. Lower 18 
panel showing the expression of RETC634R-Fc as well as the purification of the dimeric RETC634R after Fc tag 19 
cleavage by TEV protease. S[O] represents the thiol oxidization of the C630 residue.  20 
 21 
Figure 8. Anti-RET WB showing the expression of RETC634R-Fc, RETC634R*-Fc, RETC634R-G4S-Fc and 22 
RETC634R*-G4S-Fc as well as RET
C634R and RETC634R* dimer after Fc tag removal. A G4S linker was introduced 23 
between TEV protease cleavage site and Fc tag in the constructs for RETC634R-Fc and RETC634R*-Fc expression 24 
to compare TEV protease cleavage efficiency. Samples were prepared under non-reducing (- DTT) and 25 
reducing conditions (+ DTT). B: Protein A beads; S: Supernatant sample after spinning down the beads. 26 
 28 
 1 
Figure 9. Purification of RETC634R and RETC634R-Fc expressed in HEK293T cells. A) Coomassie-stained 2 
SDS-PAGE image showing purified extracellular domain of RETC634R with an Fc tag and RETC634R dimer 3 
under reducing (right panel) and non-reducing conditions (left panel); B) SEC profile showing RETC634R 4 
dimer and monomer separation using an S200 increase 5/150 column.  5 
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Supplementary Information 
Pull-down assays 
Comparing the activity of RETECD expressed using CHO-K1 and HEK293T cells 
In brief, RETECD expressed using either CHO-K1 or HEK293T cells was added to pre-incubated Fc-
GDF15/GFRAL mixture and the final concentration of RETECD, GFRAL and Fc-GDF15 was 2.5 M, 2.5 M 
and 1.25 M, respectively. After 1-hr incubation at 4 ̊ C, 5 l protein A resin was added to each sample together 
with 400 l binding buffer and the samples were mixed by end-to-end rotation for 2 hr at 4 ˚C. The resin was 
then washed and incubated with SDS PAGE loading buffer without DTT before electrophoresis.   
 
RETECD mutants and their binding to GDF15/GFRAL 
Single mutations of RETECD (N336Q, N343Q and N468Q) were introduced using Q5 site directed mutagenesis. 
The soluble ECDs of RETN336Q, RETN343Q and RETN468Q were expressed as described earlier for the wild-type 
RETECD and purified by Ni-NTA affinity chromatography. Pull-down assay was performed as described earlier 
and samples were analysed under non-reducing conditions using Coomassie-stained SDS-PAGE gel. 
 
Deglycosylation 
5 g of RETECD (insect) was deglycosylated using Endo Hf  or PNGase F under native and denaturing 
conditions according to the manufacturer’s protocol. Phenylmethylsulfonyl fluoride (PMSF) was 
supplemented to all samples at a final concentration of 1 mM to prevent possible proteolysis. After the addition 
of the glycosidases, the mixture was incubated at 37 ˚C for 1 hr under denaturing conditions and 4 hr under 
native conditions. Afterwards, the samples were mixed with SDS PAGE loading buffer with DTT and were 
subject to electrophoresis.  
 
Western blotting  
For western blotting, proteins were transferred to 0.2 µm nitrocellulose membrane with the Trans-Blot Turbo 
transfer system and membranes were blocked with 3% BSA in TBST for 30 min. After being probed with 
appropriate antibodies, the membranes were washed three times in TBST, developed with enhanced 
chemiluminescence (ECL) substrate and imaged using a ChemiDoc XRS+ System (Bio-Rad) to detect bound 
antibodies.  Anti-RET(C-3)-HRP conjugated antibody was used at 1:1000 dilution in blocking buffer. Anti-
5xHIS antibody was used at 1:5000 dilution in blocking buffer and horseradish peroxidase (HRP) conjugated 
mouse IgG kappa binding protein (m-IgGκ BP-HRP) secondary antibody was used at 1:5000 dilution in 10% 
non-fat milk dissolved in TBS.  
 
Supplementary Table 1. Approaches used to express RETECD using mammalian cells.  
Target 
protein 











Stable cell line [20] 
RET-TEV-His6 / CHO  Transient [17] 


























Supplementary Figure 1. Western blot images showing RETECD expression using HEK293T, CHO-K1 and 
CHO cells under various conditions. A) The expression of RETECD in HEK293T cells transfected using 
different DNA:PEI ratios; B) The expression of RETECD in CHO and CHO-K1 cells 10- or 11-day post-
transfection at 33 ˚C. C) Time dependent expression of RETECD using HEK293T and CHO-K1 cells at 33 ˚C 





Supplementary Figure 2. Coomassie-stained SDS PAGE gel image showing RETECD expressed in CHO-K1 
and HEK293T cells pulled down by GDF15/GFRAL. RET pulled down is marked with a star. All samples 





Supplementary Figure 3. Deglycosylation of RETECD (insect) by Endo Hf and PNGase F under native and 
denaturing conditions. Non-treated RETECD has a MW of 95kDa while the calculated MWs of RETECD treated 
by EndoHf and PNGase are 90 and 75 kDa, respectively. All samples are treated with SDS loading dye with 






Supplementary Figure 4. Anti-RET WB showing the expression of RETC634R-Fc, RETC630A,C634R-Fc and 
RETC634R dimer after Fc tag removal (marked by the black stars). Samples were prepared under non-reducing 




Supplementary Figure 5. Expression of RETECD mutants in HEK293T cells and their binding to 
GDF15/GFRAL. All samples are treated with SDS loading dye without DTT. A) Anti-HIS western blot 
showing the expression of different RETECD mutants N336Q, N343Q and N468Q. Expression was done in 
duplicates. B) Coomassie-stained gel image showing the protein A resin pull down of different RETECD 
mutants by Fc-GDF15/GFRAL. C) The table shows the band intensity as measured by ImageJ (Area (U)). 
Bands correspond to the wild-type RETECD and mutants are labelled (1 for N343Q, 2 for N336Q and 3 for 
wild-type). U: units. 
 
 
 
 
 
